Frontiers in Anti-Cancer Drug Discovery Volume 4

By Atta-ur-Rahman, FRS

Development of safe and effective anti-cancer drugs is one the most active areas of  scientific research today and it is likely to remain so for years to come. Cancers cause  more deaths than any other single disease, both in the developed and developing world.
Prognosis in many forms of cancers is often glimpsed, despite major development in  surgery and radiotherapy. Development of cancer chemotherapy remains an important  challenge. The major bottleneck in the development of safe and effective anti-cancer
drugs is the complex nature of the disease, involving still far from perfect  understanding of the disease process at the molecular level, heterogeneity, and  environmental factors. Emergence of resistance against existing drugs is yet another  challenge to be faced.
Research and development in the area of anti-cancer therapies are overwhelming. For  researchers working in this field, it is often difficult to keep track of and benefit from  the key developments. The eBook series, “Frontiers in Anti-Cancer Drug Discovery”, is intended to represent the most notable developments in the field in the form of cutting edge reviews written by the leading experts.

Volume 4 of the eBook series, “Frontiers in Anti-Cancer Drug Discovery”, is a compilation of six well written and well referenced chapters contributed by some of the most prominent researchers in the field of cancer chemotherapy. Munoz and Coveñas
skillfully review the role of peptide substance P (SP), and the NK-1 receptor in cancer progression, especially migration of tumor cells, angiogenesis and antiapoptotic effects.  Based on this, they have discussed the relevance of NK-1 receptor antagonists in
blocking the function of SP, thus serving as “Intelligent Bullets” against cancer.


This content is for gold members only. Log In or Register to see
Tags: ,

Comments are closed.